Safety and immunogenicity of the Intradermal thai red cross (2-2-2-0-1-1) post exposure vaccination regimen in the Indian population using purified chick embryo cell rabies vaccine

• Published in: Indian journal of medical microbiology Vol. 23; no. 1; pp. 24 - 28
• Main Author: Chhabra Mala, Ichhpujani RL, Bhardwaj M, Tiwari KN, Panda RC, Lal S
• Format: Journal Article
• Language: English
• Published: India Medknow Publications on behalf of Indian Association of Medical Microbiology 01.01.2005; Elsevier B.V
• Subjects: Animals; Antibodies, Viral - biosynthesis; Chick Embryo; Humans; Immunization Schedule; Immunoglobulins - analysis; India; Injections, Intradermal; intradermal administration; post-exposure prophylaxis; Rabies; Rabies - immunology; Rabies - prevention & control; rabies antibody; Rabies Vaccines - administration & dosage; Rabies Vaccines - adverse effects; Rabies Vaccines - immunology; Red Cross; Safety; Thailand; tissue culture rabies vaccine; Vaccination; Thailand; India; rabies antibody; tissue culture rabies vaccine; intradermal administration; post-exposure prophylaxis; Rabies
• ISSN: 0255-0857
• DOI: 10.1016/S0255-0857(21)02707-9

PURPOSE: To test the immunogenicity of the WHO recommended "2-2-2-0-1-1" post-exposure rabies vaccination regimen in Indian subjects to determine the feasibility of replacing crude sheep brain nerve tissue rabies vaccine with modern tissue culture rabies vaccine at major anti-rabies treatment centers throughout India. METHODS: Purified chick embryo cell vaccine (PCECV) was administered in the dosage of 0.1mL per site to 53 Indian subjects. RESULTS: All subjects produced rabies antibodies above 0.5IU/mL by day 14 post-vaccination. Only minor adverse reactions including swelling (6.6%), erythema (5.4%) and pain (1.4%) were observed for which no treatment was required. CONCLUSIONS: This study demonstrated that PCECV is safe and highly immunogenic in Indian subjects when administered intradermally as 0.1mL/site using the "2-2-2-0-1-1" post-exposure regimen.